Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Actinogen Medical ( (AU:ACW) ) is now available.
Actinogen Medical has announced the early completion of pTau screening in its XanaMIA Alzheimer’s trial due to strong recruitment, with final results expected by mid-Q4 2026. The increased participant enrollment is set to enhance the trial’s statistical power, potentially strengthening Xanamem’s positioning as a viable oral therapy for Alzheimer’s, offering safety and efficacy advantages over existing treatments.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a promising treatment for Alzheimer’s Disease and Depression, with potential future applications in Fragile X Syndrome and other related conditions.
YTD Price Performance: 20.0%
Average Trading Volume: 2,595,143
Technical Sentiment Signal: Hold
Current Market Cap: A$95.26M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.